Spero Therapeutics Inc SPRO.OQ SPRO.O is expected to show a fall in quarterly revenue when it reports results on November 14 for the period ending January 1 0001
The Cambridge Massachusetts-based company is expected to report a 69.9% decrease in revenue to $7.667 million from $25.47 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Spero Therapeutics Inc is for a loss of 36 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Spero Therapeutics Inc is $5.00, above its last closing price of $1.31.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jan. 1 0001 | -0.34 | -0.38 | -0.33 | Beat | 13.2 |
Mar. 31 0001 | -0.04 | -0.04 | -0.24 | Missed | -453.9 |
Dec. 31 2023 | -0.23 | -0.10 | 0.96 | Beat | 1,060 |
Sep. 30 2023 | -0.02 | -0.03 | 0.04 | Beat | 233.3 |
Jun. 30 2023 | -0.33 | -0.34 | -0.23 | Beat | 33 |
Mar. 31 2023 | -0.33 | -0.33 | -0.25 | Beat | 25 |
Dec. 31 2022 | 0.04 | 0.55 | Beat | 1,169.3 | |
Jan. 1 0001 | -0.31 | -0.30 | -0.33 | Missed | -8.8 |
This summary was machine generated November 8 at 15:48 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。